Allergen-specific immunotherapy (AIT) is the only 'cause-specific' treatment method that changes the natural course of allergic diseases by inducing the body to establish immune tolerance through long-term, repeated administration of specific allergens. With the continuous rise in the prevalence of allergic diseases, patients' understanding of AIT therapy deepening, and rapid breakthroughs in new technologies such as molecular allergens and recombinant allergens, AIT is entering a critical development period from 'empirical treatment' to 'precision immune regulation'.
Against this backdrop, Frost & Sullivan (hereinafter referred to as 'Frost & Sullivan') has authored the 'Global Allergen-Specific Immunotherapy Industry Development Blue Book 2026' (hereinafter referred to as the 'Blue Book'). The Blue Book aims to conduct an in-depth analysis of the field of allergen-specific immunotherapy, providing a comprehensive exposition from multiple dimensions such as the epidemiology of allergic diseases, types and sensitization mechanisms of allergens, the evolution of AIT technology, iterations in delivery pathways, unmet clinical needs, and future development trends. It tracks the context of industry and technological development, explores the tremendous potential for industry growth, and analyzes the driving factors behind market development.
Allergen-specific immunotherapy (AIT) is the only "causative treatment" that alters the natural course of allergic diseases by inducing immunological tolerance through long-term, repeated administration of specific allergens to patients. Amid the continuously rising prevalence of allergic diseases, patients' growing awareness of AIT, and rapid breakthroughs in next-generation technologies such as molecular allergens and recombinant allergens, AIT is entering a critical development phase, transitioning from "empirical treatment" to "precise immunomodulation."
Against this backdrop, Frost & Sullivan has prepared the 2026 Global Allergen Specific Immunotherapy Development Blue Book, which provides an in-depth analysis of the field of allergen specific immunotherapy, offering a comprehensive exposition from multiple perspectives, including the epidemiology of allergic diseases, types of allergens and sensitization mechanisms, the evolution of AIT technologies, iterations of administration routes, unmet clinical needs, and future development trends. It traces the technological and developmental trajectory of the industry, explores its significant potential, and analyzes the driving factors behind market growth.
